Sales and Marketing

Showing 15 posts of 11526 posts found.

PCI Pharma Services’ Ian Parsonage to Share Serialization Expertise at Global Track & Trace Conference

April 21, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ian parsonage, pci pharma, serialisation

Ian Parsonage, Senior Director of Global Serialization for leading pharmaceutical services provider PCI Pharma Services, will present at the Global …
figures_charts

Shares plunge at Sarepta after negative FDA review on muscle disorder drug

April 21, 2016 Research and Development, Sales and Marketing FDA, Sarepta Therapeutics, Shares, dive, fall, negative, plunge, sarepta

Sarepta Therapeutics (NASDAQ: SPRT) is counting the cost as shares plunge following a negative review given by staff at the …
gwpharma

GW Pharma’s cannabis-based epilepsy drug granted orphan designation by FDA

April 21, 2016 Research and Development, Sales and Marketing GW Pharma, cannabis, cannabis-based, epilepsy

GW Pharmaceuticals (NASDAQ: GWPH) has announced that the US Food and Drug Administration has granted its cannabis-based epilepsy drug, Epidiolex …
amgen_flag

Amgen’s drug reduces rates of bleeding in rare childhood disorder

April 21, 2016 Research and Development, Sales and Marketing Amgen, blood disorder, children, nplate, paediatric, platelet, rare, romisplostim

Amgen (NASDAQ: AMGN) has announced the results of a Phase III trial, published in The Lancet, which shows that Nplate …
novartis_side_building

Novartis Q1 earnings drop as cancer drug sales falter

April 21, 2016 Business Services, Sales and Marketing Financial, Novartis, earnings, first quarter, results

Swiss drugmaker Novartis (SIX: NOVN) on Thursday reported a 13% drop in net income for the first quarter on the …
abbvie_0

Abbvie acquires immune-oncology target from argenx

April 21, 2016 Research and Development, Sales and Marketing AbbVie, Protein, argenx, garp, immuno-oncology, immunosuppresive

AbbVie (NYSE:ABBV) has announced the acquisition of a new preclinical-stage human antibody program evaluating the novel immune-oncology target GARP, a …

Illumina shares plunge as it cuts Q1 outlook

April 20, 2016 Research and Development, Sales and Marketing Financial, Illumina, Share price, Shares, outlook, revenue, stock market

Shares in Illumina (Nasdaq: ILMN) plunged after the company cut its revenue estimates for the first quarter based on low …
opdivo_1_1

Focus: Bristol-Myers Squibb’s wonder drug – Opdivo

April 20, 2016 Research and Development, Sales and Marketing BMS, growth, immuno-oncology, opdivo, sales

By Anjali ShuklaNew data for Bristol-Myers Squibb’s (NYSE: BMY) Opdivo to treat head and neck cancer showed superior survival compared with …
bi_microparts_image

Boehringer Ingelheim posts 11% rise in FY15 sales boosted by diabetes business

April 20, 2016 Business Services, Research and Development, Sales and Marketing Boehringer Ingelheim, FY, earnings, forecasts, outlook, results

Boehringer Ingelheim reported 11% jump in sales for 2015 driven by its diabetes business and said for 2016 it sees …
gilead-sciences

Gilead presents data highlighting progress and efficacy in liver and hepatitis C therapies

April 20, 2016 Research and Development, Sales and Marketing Gilead, harvoni, hepatitis, liver, sofosbuvir

Gilead (NASDAQ: GILD) has presented a broad range of results on its current and potential therapeutics at the International Liver …
jj_sign_on_wall

J&J raises FY outlook, Q1 beats estimates

April 20, 2016 Business Services, Research and Development, Sales and Marketing Financial, Johnson & Johnson, Q1, earnings, results, revenue, sales

Healthcare giant Johnson & Johnson (NYSE: JNJ) raised its full-year outlook and posted first-quarter earnings ahead of estimates despite currency headwinds. …
whats_up_doc

Lemtrada shows clinical efficacy in multiple sclerosis in 10-year follow-up data

April 20, 2016 Research and Development, Sales and Marketing Lemtrada, Sanofi, alemtuzumab, multiple sclerosis, sanofi genzyme

Sanofi Genzyme has presented 10-year follow-up data on Lemtrada (alemtuzumab) which points to its efficacy in patients with relapsing-remitting multiple …
opdivo_1

Opdivo shows biggest survival increase for head and neck cancer in 20 years in Phase III trials

April 19, 2016 Research and Development, Sales and Marketing Bristol-Myers Squibb, Cancer, blockbuster, head and neck cancer, nivolumab, oncology, opdivo, potential, squamous

Opdivo (nivolumab) showed the biggest increase in survival for patients with head and neck cancer for 20 years, according to …
roche_dark_0

Roche reports 5% rise in Q1 sales boosted by cancer drugs

April 19, 2016 Manufacturing and Production, Sales and Marketing Q1, Roche, earnings, oncology drugs, results

Oncology drug maker Roche (VTX: ROG) on Tuesday reported 5% increase in first-quarter sales driven by cancer drugs. The company …
eli_lilly_logo

Eli Lilly drops development of diabetes drug in Phase III

April 19, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Eli Lilly, Transition Therapeutics, diabetes, drug trial

US drugmaker Eli Lilly (NYSE: LLY) has pulled out of the partnership with Transition Therapeutics (TSX: TTH) to develop its …
The Gateway to Local Adoption Series

Latest content